From https://projects.propublica.org/docdollars. © Copyright 2013 Pro Publica Inc.
Amgen
Amgen, a biotechnology company with headquarters in Thousand Oaks, Calif., pleaded guilty in December 2012 to illegally introducing the drug Aranesp into the market for uses not approved by the U.S. Food and Drug Administration. The company also paid $762 million to resolve criminal and civil charges relating to its conduct with Aranesp and other drugs. In April 2013, Amgen agreed to pay another $24.9 million to resolve allegations that it gave kickbacks to long-term care pharmacies that provide Aranesp to nursing homes.
Amgen began reporting payments for consulting, speaking, meals, travel and educational items as of January 2013. It also reports research payments in a separate report, beginning in July 2013.
Amgen's 2013 U.S. sales: $14.8 billion. Source: IMS Health.
See all Amgen payments, or visit Amgen's transparency page.
Notable drugs
- Neulasta (Makes white blood cells, prevents infections during cancer treatments)
- Neupogen (Makes white blood cells, prevents infections during cancer treatments)
- Enbrel (Rheumatoid arthritis, psioratic arthritis, ankylosing spondylitis, plaque psoriasis in adults, juvenile idiopathic arthritis)
- Arenesp (Anemia via kidney failure or chemotherapy)
- Epogen (Anemia)
- Sensipar (Lowers calcium in blood)
- Vectibix (Metastatic cancer of the colon or rectum)
- Nplate (Chronic immune thrombocytopenia)
- Xgeva (Osteoporosis, bone cancer, bone related problems in cancer patients)
- Prolia (Osteoporosis, bone cancer, bone related problems in cancer patients)
- Kyprolis (Multiple myeloma)
Payment Reports
2013 Jan. to Dec.
| Avg. Quarterly | Total | |
|---|---|---|
| Speaking/Other | $1,497,107 | $5,988,429 |
| Consulting | $885,571 | $3,542,282 |
| Meals | $785,974 | $3,143,897 |
| Travel | $571,678 | $2,286,714 |
| Items, Gifts | $45,593 | $182,372 |
| Speaking | $775 | $3,100 |
| Other | $656 | $2,625 |
| $3,787,355 | $15,149,419 |
2013 Jan. to Dec. Research
| Avg. Quarterly | Total | |
|---|---|---|
| Research | $6,704,638 | $26,818,551 |
| Adjustment | -$270 | -$1,080 |
| $6,704,368 | $26,817,471 |
Total Payments by State
| State | Total |
|---|---|
| California | $6,134,910 |
| Texas | $3,786,680 |
| New York | $2,814,761 |
| Florida | $1,775,828 |
| North Carolina | $1,908,112 |
| Pennsylvania | $1,546,819 |
| Illinois | $1,455,308 |
| Ohio | $1,377,379 |
| Michigan | $1,210,336 |
| Massachusetts | $1,091,015 |
| Maryland | $1,189,262 |
| Alabama | $957,129 |
| Tennessee | $1,150,024 |
| Georgia | $776,618 |
| South Carolina | $706,044 |
| Virginia | $699,743 |
| Washington | $680,931 |
| Nebraska | $1,328,117 |
| Kentucky | $634,447 |
| New Jersey | $593,469 |
| Minnesota | $3,889,922 |
| Missouri | $502,894 |
| Nevada | $471,818 |
| Arizona | $459,351 |
| District of Columbia | $445,145 |
| Indiana | $412,952 |
| Connecticut | $393,552 |
| Kansas | $351,756 |
| Colorado | $332,626 |
| Louisiana | $300,955 |
| Wisconsin | $299,785 |
| New Mexico | $293,355 |
| Arkansas | $222,013 |
| Iowa | $203,886 |
| Utah | $196,354 |
| Puerto Rico | $172,551 |
| Rhode Island | $139,878 |
| Oklahoma | $139,670 |
| Oregon | $135,655 |
| Idaho | $114,058 |
| Mississippi | $126,016 |
| North Dakota | $103,975 |
| West Virginia | $80,202 |
| Maine | $79,984 |
| Montana | $76,982 |
| New Hampshire | $52,980 |
| South Dakota | $47,767 |
| Hawaii | $45,899 |
| Delaware | $32,630 |
| Vermont | $19,191 |
| Alaska | $3,698 |
| Wyoming | $2,128 |
| [Unknown State] | $329 |
What Companies Disclose
See which services pharmaceutical companies report paying health practitioners for.
Big Pharma’s Big Fines
Drug companies have paid billions to the Department of Justice to resolve allegations of health care fraud. See some of the biggest settlements.
